# Replagal Enzyme Replacement Therapy for Adults With Fabry Disease

> **NCT00097890** · PHASE4 · COMPLETED · sponsor: **National Institute of Neurological Disorders and Stroke (NINDS)** · enrollment: 25 (—)

## Conditions studied

- Fabry Disease

## Interventions

- **DRUG:** Replagal (Agalsidase Alfa)
- **DRUG:** Replagal

## Key facts

- **NCT ID:** NCT00097890
- **Lead sponsor:** National Institute of Neurological Disorders and Stroke (NINDS)
- **Sponsor class:** NIH
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** —
- **Final completion:** 2005-12
- **Target enrollment:** 25 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00097890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00097890, "Replagal Enzyme Replacement Therapy for Adults With Fabry Disease". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00097890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*